Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Net Income (2016 - 2025)

Historic Net Income for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $390.9 million.

  • Tg Therapeutics' Net Income rose 1000623.06% to $390.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.5 million, marking a year-over-year increase of 321281.3%. This contributed to the annual value of $23.4 million for FY2024, which is 8452.49% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Net Income is $390.9 million, which was up 1000623.06% from $28.2 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Net Income ranged from a high of $390.9 million in Q3 2025 and a low of -$94.0 million during Q4 2021
  • Over the past 5 years, Tg Therapeutics' median Net Income value was -$36.6 million (recorded in 2022), while the average stood at -$6.2 million.
  • In the last 5 years, Tg Therapeutics' Net Income tumbled by 9660.49% in 2024 and then soared by 1000623.06% in 2025.
  • Quarter analysis of 5 years shows Tg Therapeutics' Net Income stood at -$94.0 million in 2021, then grew by 14.49% to -$80.4 million in 2022, then surged by 82.07% to -$14.4 million in 2023, then surged by 261.92% to $23.3 million in 2024, then surged by 1574.7% to $390.9 million in 2025.
  • Its Net Income was $390.9 million in Q3 2025, compared to $28.2 million in Q2 2025 and $5.1 million in Q1 2025.